The stock will trade on pipeline catalysts, not quarterly financials. Key binary event is the mid-2026 monotherapy data update for MICVO in 2L+ HNSCC, which will determine whether the dose-cap strategy preserves efficacy while improving safety. Cash runway into Q4 2026 provides ~2 quarters of operating visibility post-data, a positive readout could trigger financing, while a negative one would raise survival risk. Monitor for any early look at the data via abstract releases or investor events.
PYXS drugs
PYXS drug pipeline →Price Chart
Executive Summary
Pyxis Oncology reported Q1 2026 financial results, with a net loss of $23.3M ($0.37/share) vs $21.2M ($0.35/share) in Q1 2025, reflecting increased R&D spending on its lead ADC candidate MICVO. The company completed target enrollment in the Phase 1 monotherapy expansion study and remains on track for key mid-2026 and 2H26 data readouts. Cash runway extends into Q4 2026, but the cash burn rate accelerated, with cash and investments declining from $68.3M (Dec 2025) to $42.5M (Mar 2026).
Key Financial Metrics
Key Facts
- Net loss of $23.3M ($0.37/share) for Q1 2026 vs $21.2M ($0.35/share) in Q1 2025
- Cash, cash equivalents, restricted cash, and short-term investments of $42.5M as of March 31, 2026, down from $68.3M at Dec 31, 2025
- R&D expenses increased to $20.0M from $17.0M YoY, driven by clinical trial costs for MICVO
- Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in Q1 2026
- Updated monotherapy data on track for mid-2026; updated combination data with pembrolizumab on track for 2H26
- Appointed Nelson Azoulay as Chief Business Officer in May 2026
- Cash runway expected into Q4 2026
Financial Impact
Net loss widened by $2.1M YoY; cash burn of ~$25.8M in Q1 2026
Risk Factors
- Cash runway only into Q4 2026, financing risk if data disappoints or enrollment slows
- Phase 1 monotherapy data in mid-2026 is binary: dose-cap strategy may reduce efficacy vs the 46% ORR seen in the preliminary December 2025 dataset
- Single-asset clinical-stage biotech, any safety or efficacy signal failure would be value-destructive
- No revenue from product sales, fully dependent on non-dilutive funding and capital markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-222818 |
| Document: pyxs-20260514.htm | 0001193125-26-222818 |
| Document: 0001193125-26-222818-index-headers.html | 0001193125-26-222818 |
| Document: 0001193125-26-222818-index.html | 0001193125-26-222818 |
| Document: 0001193125-26-222818.txt | 0001193125-26-222818 |
| 8-K Data (Synthetic) | 0001193125-26-222818 |
Track record
25 reports on PYXS
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.94% at T+60 after the Apr 17, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.43 Now $1.41 −1.32% settles Dec 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.43 Now $1.41 −1.40% settles Dec 16
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.55 Now $1.41 −9.14% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $1.61 Now $1.41 −12.42% settles Dec 4
- Nov 3, 202613d ago SC 13G/A Bearish 5/10 Entry $1.64 Now $1.41 +14.02% settles Dec 2
- Oct 27, 202620d ago Press Release Neutral 4/10 Entry $1.84 Now $1.41 −23.37% settles Nov 24
- Oct 21, 202626d ago DEF 14A Bearish 6/10 Entry $1.71 Now $1.41 +17.54% settles Nov 19
- Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $2.03 to $1.66 Now $1.41 −30.54% ▼ −18.23% −12.67% vs SPY
- Oct 2, 20266w ago SC 13G/A Neutral 4/10 Entry $2.14 to $1.81 Now $1.41 −34.11% ▼ −15.42% −13.61% vs SPY
- Oct 2, 20266w ago Press Release Bearish 7/10 Entry $2.14 to $1.81 Now $1.41 +34.11% ▲ +15.42% +13.61% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers